Aop:57

From AOP-Wiki
Revision as of 19:06, 11 December 2016 by Sedwar02 (Talk | contribs)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search

Status

This is a legacy representation of this AOP. Please see the current version here:

https://aopwiki.org/aops/57


AOP Title

AhR activation leading to hepatic steatosis
Short name: AhR activation to steatosis

Authors

Michelle Angrish

Status

Please follow the link to snapshots page to view and create Snapshots of this AOP.

OECD Project 1.29: A catalog of putative AOPs that will enhance the utility of US EPA Toxcast high throughput screening data for hazard identification

Under development: Do not distribute or cite.

This AOP page was last modified on 12/11/2016.

Click here to show/hide revision dates for related pages

Page Revision Date/Time

Abstract

Background (optional)

Summary of the AOP

Please follow link to widget page to edit this section.

If you manually enter text in this section, it will get automatically altered or deleted in subsequent edits using the widgets.

Molecular Initiating Event

Molecular Initiating Event Support for Essentiality
AHR, Activation Strong

Key Events

Event Support for Essentiality
VLDL secretion, Suppression Strong
Mitochondrial fatty acid beta-oxidation, Inhibition Strong
Fatty acid, Accumulation Strong
PCK1 expression (control point for glycolysis/gluconeogenesis pathway), Decreased Strong
Triglyceride, Accumulation Strong
CD36, Up Regulation Strong
SCD-1, Increased Moderate
FA Influx, Increased Strong
LDLR (low density lipoprotein receptor), Up Regulation Strong
LDL uptake, Increased
CYP1A1, Up Regulation Strong

Adverse Outcome

Adverse Outcome
Liver lipid, Accumulation

Relationships Among Key Events and the Adverse Outcome

Event Description Triggers Weight of Evidence Quantitative Understanding
VLDL secretion, Suppression Directly Leads to Liver lipid, Accumulation Strong Strong
AHR, Activation Indirectly Leads to Mitochondrial fatty acid beta-oxidation, Inhibition Moderate Moderate
Triglyceride, Accumulation Directly Leads to Liver lipid, Accumulation Strong Strong
Mitochondrial fatty acid beta-oxidation, Inhibition Directly Leads to Fatty acid, Accumulation Strong Strong
AHR, Activation Directly Leads to CD36, Up Regulation Strong Strong
AHR, Activation Directly Leads to SCD-1, Increased Moderate
AHR, Activation Directly Leads to PCK1 expression (control point for glycolysis/gluconeogenesis pathway), Decreased Strong Strong
SCD-1, Increased Directly Leads to Triglyceride, Accumulation Strong
CD36, Up Regulation Directly Leads to FA Influx, Increased Strong
Fatty acid, Accumulation Directly Leads to Liver lipid, Accumulation Strong Strong
PCK1 expression (control point for glycolysis/gluconeogenesis pathway), Decreased Indirectly Leads to Fatty acid, Accumulation
FA Influx, Increased Directly Leads to Fatty acid, Accumulation
AHR, Activation Directly Leads to LDLR (low density lipoprotein receptor), Up Regulation Strong
LDLR (low density lipoprotein receptor), Up Regulation Directly Leads to LDL uptake, Increased
LDL uptake, Increased Directly Leads to Fatty acid, Accumulation
AHR, Activation Indirectly Leads to VLDL secretion, Suppression
AHR, Activation Directly Leads to CYP1A1, Up Regulation Strong

Network View

   Cytoscape Web will replace the contents of this div with your graph.

Click nodes or edges.

Life Stage Applicability

Life Stage Evidence Links

Taxonomic Applicability

Name Scientific Name Evidence Links
mouse Mus musculus Strong NCBI

Sex Applicability

Sex Evidence Links

Graphical Representation

Click to upload graphical representation

Overall Assessment of the AOP

Domain of Applicability

Life Stage Applicability, Taxonomic Applicability, Sex Applicability
Elaborate on the domains of applicability listed in the summary section above. Specifically, provide the literature supporting, or excluding, certain domains.

Essentiality of the Key Events

Molecular Initiating Event Summary, Key Event Summary
Provide an overall assessment of the essentiality for the key events in the AOP. Support calls for individual key events can be included in the molecular initiating event, key event, and adverse outcome tables above.

Weight of Evidence Summary

Summary Table
Provide an overall summary of the weight of evidence based on the evaluations of the individual linkages from the Key Event Relationship pages.

Quantitative Considerations

Summary Table
Provide an overall discussion of the quantitative information available for this AOP. Support calls for the individual relationships can be included in the Key Event Relationship table above.

Considerations for Potential Applications of the AOP (optional)

References